SG11202011961YA - Dosing and effect of c5a antagonist with anca-associated vasculitis - Google Patents

Dosing and effect of c5a antagonist with anca-associated vasculitis

Info

Publication number
SG11202011961YA
SG11202011961YA SG11202011961YA SG11202011961YA SG11202011961YA SG 11202011961Y A SG11202011961Y A SG 11202011961YA SG 11202011961Y A SG11202011961Y A SG 11202011961YA SG 11202011961Y A SG11202011961Y A SG 11202011961YA SG 11202011961Y A SG11202011961Y A SG 11202011961YA
Authority
SG
Singapore
Prior art keywords
anca
antagonist
dosing
effect
associated vasculitis
Prior art date
Application number
SG11202011961YA
Other languages
English (en)
Inventor
Jun Deng
Petrus Bekker
Jan Hillson
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of SG11202011961YA publication Critical patent/SG11202011961YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202011961YA 2018-06-07 2019-06-06 Dosing and effect of c5a antagonist with anca-associated vasculitis SG11202011961YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862682013P 2018-06-07 2018-06-07
PCT/US2019/035758 WO2019236820A1 (en) 2018-06-07 2019-06-06 Dosing and effect of c5a antagonist with anca-associated vasculitis

Publications (1)

Publication Number Publication Date
SG11202011961YA true SG11202011961YA (en) 2020-12-30

Family

ID=68764799

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011961YA SG11202011961YA (en) 2018-06-07 2019-06-06 Dosing and effect of c5a antagonist with anca-associated vasculitis

Country Status (15)

Country Link
US (2) US11191756B2 (OSRAM)
EP (1) EP3801519A4 (OSRAM)
JP (2) JP2021527062A (OSRAM)
KR (2) KR20210018906A (OSRAM)
CN (1) CN112423752A (OSRAM)
AU (1) AU2019282327B2 (OSRAM)
BR (1) BR112020024842A2 (OSRAM)
CA (1) CA3102403A1 (OSRAM)
CL (1) CL2020003171A1 (OSRAM)
IL (1) IL279188B2 (OSRAM)
MA (1) MA52808A (OSRAM)
MX (1) MX2020013166A (OSRAM)
SG (1) SG11202011961YA (OSRAM)
WO (1) WO2019236820A1 (OSRAM)
ZA (1) ZA202007615B (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3102403A1 (en) 2018-06-07 2019-12-12 Chemocentryx, Inc. Dosing and effect of c5a antagonist with anca-associated vasculitis
EP4487915A3 (en) 2018-11-30 2025-03-19 ChemoCentryx, Inc. Capsule formulations
MX2022005406A (es) 2019-11-08 2022-05-24 Chemocentryx Inc Forma amorfa de un receptor de componente c5a de complemento.
CN118908883A (zh) * 2019-11-08 2024-11-08 凯莫森特里克斯股份有限公司 补体成分c5a受体的盐形式

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
WO2008079371A1 (en) * 2006-12-22 2008-07-03 Encysive Pharmaceuticals, Inc. Modulators of c3a receptor and methods of use thereof
CN104193824A (zh) * 2008-02-20 2014-12-10 G2炎症私人有限公司 人源化抗-C5aR抗体
US20110275639A1 (en) * 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
SMT202200074T1 (it) 2008-12-22 2022-03-21 Chemocentryx Inc Antagonisti di c5ar
HRP20171176T1 (hr) 2010-06-24 2017-10-06 Chemocentryx, Inc. C5ar antagonisti
EP3682879B1 (en) 2014-09-29 2022-08-03 ChemoCentryx, Inc. Processes and intermediates in the preparation of c5ar antagonists
EP3283889B1 (en) 2015-04-17 2020-02-26 Euroimmun Medizinische Labordiagnostika AG Method and assay for diagnosing rapidly progressive glomerulonephritis in a subject
WO2017176620A2 (en) 2016-04-04 2017-10-12 Chemocentryx, Inc. SOLUBLE C5aR ANTAGONISTS
US20190134020A1 (en) * 2017-10-31 2019-05-09 Chemocentryx, Inc. C5aR INHIBITOR REDUCTION OF URINARY sCD163
CA3102403A1 (en) 2018-06-07 2019-12-12 Chemocentryx, Inc. Dosing and effect of c5a antagonist with anca-associated vasculitis

Also Published As

Publication number Publication date
JP2021527062A (ja) 2021-10-11
CN112423752A (zh) 2021-02-26
JP2024114706A (ja) 2024-08-23
EP3801519A1 (en) 2021-04-14
BR112020024842A2 (pt) 2021-03-02
MX2020013166A (es) 2021-03-29
US12350263B2 (en) 2025-07-08
US11191756B2 (en) 2021-12-07
KR20210018906A (ko) 2021-02-18
WO2019236820A1 (en) 2019-12-12
US20190374524A1 (en) 2019-12-12
EP3801519A4 (en) 2022-03-30
AU2019282327B2 (en) 2025-04-24
CL2020003171A1 (es) 2021-06-04
AU2019282327A1 (en) 2021-01-07
MA52808A (fr) 2021-04-14
IL279188B1 (en) 2025-12-01
IL279188B2 (en) 2026-04-01
KR20260027358A (ko) 2026-02-27
ZA202007615B (en) 2024-05-30
IL279188A (en) 2021-01-31
US20220296576A1 (en) 2022-09-22
CA3102403A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
IL279188A (en) Dose and effect of C5A antagonists with ANCA-associated vasculitis
IL288457A (en) Humanized anti-human CD19 antibodies and methods of use
IL255336A0 (en) Chimeric antigen receptors and methods of using them
ZA201705720B (en) Anti-dll3 chimeric antigen receptors and methods of use
IL258394B (en) Anti-tigit antigen binding proteins and methods of their use
IL255278A0 (en) Anti-ox40 antibodies and methods of using them
SG10201912519VA (en) Chimeric receptors and methods of use thereof
IL248481A0 (en) Animals containing c5 and c3 of human origin
HUE073235T2 (hu) Anti-HER2 antitestek és alkalmazási eljárások
SG11201707886WA (en) Humanized anti-c1s antibodies and methods of use thereof
ZA201801048B (en) Encoderless motor with improved granularity and methods of use
IL252929B (en) Anti-acth antibodies from humans and their use
IL254951A0 (en) Monoclonal antibodies of influenza of human origin and methods of using them
PT3717650T (pt) ¿vento de milho mon87429 e seus métodos de utilização
IL256997B (en) Anti-cd154 antibodies and methods of using them
IL274045B1 (en) Prodrugs of dantrolene and methods of using them
IL265761A (en) Terlipressin compounds and methods of using them
HK40050407A (en) Dosing and effect of c5a antagonist with anca-associated vasculitis
GB201509977D0 (en) Dispensers and methods of use thereof
GB201720648D0 (en) Aggregate pellets and methods of forming aggregate pellets
TWM488873U (en) Thin and long cookie structure with a plurality of granules